All federal filed Pradaxa lawsuits have been ordered by the U.S. Judicial Panel on Multidistrict Litigation to be consolidated and centralized to U.S. District Court in the Southern District of Illinois under U.S. District Judge David R. Herndon. The formation of the MDL means that any new federally filed Pradaxa lawsuits will be transferred automatically to Judge Herndon’s court for pretrial proceedings.
Praxada is an anticoagulant manufactured by Boehringer Ingelheim as a stroke preventative treatment in patients with non-valvular atrial fibrillation. The lawsuits allege that Boehringer failed to warn patients and their physicians about an increased risk of uncontrolled bleeding events and that the drug has no effective reversal agent in the case of bleeding events.
A report by the Institute for Safe Medication Practices says that after analyzing all adverse event reports submitted to the FDA regarding Pradaxa during 2011, they found 2,367 bleeding events, and 542 deaths in patients using Pradaxa.
As we have previously reported, cerebral hemorrhage, wrongful death, and internal bleeding event lawsuits have been filed against Boehringer Ingelheim over Pradaxa. Other adverse side effects associated with the drug include kidney failure and stroke.